[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-in-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-in-pregnancy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,82,109,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630009","gastric-ultrasound-after-clear-fluid-intake-in-diabetic-and-non-diabetic-pregnant-women-100630009",false,"NCT07482098","Gastric Ultrasound After Clear Fluid Intake in Diabetic and Non-Diabetic Pregnant Women","Effect of Preoperative Clear Fluid Intake on Gastric Volume in Diabetic and Non-Diabetic Pregnant Women Assessed by Gastric Ultrasonography","Inclusion Criteria:\n\n* Pregnant women aged 18-40 years\n* Scheduled for elective cesarean section under spinal anesthesia\n* Singleton pregnancy\n* ASA physical status II\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Contraindication to spinal anesthesia\n* Known allergy to study medications\n* Multiple pregnancy\n* Severe systemic disease (ASA III or higher)\n* Pre-existing neurological disease\n* Infection at the spinal puncture site","FEMALE","18 Years","40 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","Pulmonary aspiration of gastric contents during anesthesia is a serious perioperative complication associated with significant morbidity and mortality. Pregnant patients are at increased risk of aspiration due to physiological changes such as delayed gastric emptying and increased intra-abdominal pressure. In addition, diabetes may impair gastric motility because of autonomic neuropathy, potentially leading to gastroparesis and increased gastric residual volume.\n\nCurrent fasting guidelines allow the intake of clear fluids up to two hours before anesthesia. However, the effect of preoperative oral clear fluid intake on gastric volume in diabetic pregnant patients remains unclear.\n\nThis prospective observational study aims to compare gastric volume measured by gastric ultrasonography in diabetic and non-diabetic pregnant women undergoing elective cesarean delivery. All participants will receive 200 ml of water two hours before surgery. Gastric ultrasonography will be performed before fluid intake and two hours after intake to evaluate gastric volume and gastric content.\n\nThe results of this study may help improve the assessment of aspiration risk and guide perioperative fasting recommendations in pregnant patients, particularly those with diabetes.",[25,26,27],"Pregnancy","Diabetes in Pregnancy","Pulmonary Aspiration",[29,30,31,32,33,34],"Gastric Ultrasound","Cesarean Delivery","Preoperative Fasting","Gastric Volume","Aspiration Risk","Pregnant Women","RECRUITING","2026-06-02",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":39},"2025-12-01",{"date":43,"type":21},"2026-07",{"name":45,"class":46},"Ankara City Hospital Bilkent","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100606140","single-vs-multi-dose-insulin-for-glycemic-control-sugar-100606140","NCT07171684","Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","Single vs Multi-Dose Insulin for Glycemic Control (SUGAR): A Randomized Noninferiority Trial","SUGAR","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus or A2 gestational diabetes mellitus requiring insulin use during pregnancy\n* Aged between 18-50\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Pre-existing use of insulin\n* Gestational Age \\> or = 35w0d\n* Planning to follow-up with a doctor not associated with RWJ Barnabas or NYU Langone Health and\u002For deliver at a hospital other than RWJUH or NYU\n* Unwilling or unable to upload or email weekly blood sugar logs\n* Contraindication to Lispro or Lantus insulin, or patient chooses to not utilize insulin therapy\n* Fetal anomaly present","50 Years",{"count":58,"type":21},176,"INTERVENTIONAL",[61],"NA","The goal of this clinical trial is to see if diabetes in pregnancy can be treated with once daily dosing of insulin instead of once daily dosing plus insulin with meals. The main question this study aims to answer is:\n\n1. Can a once daily dose of long-acting insulin control blood sugars as well as long-acting insulin plus meal-time insulin?\n2. Do babies born to mothers who take one dose of long-acting insulin have more complications after birth than babies born to mothers who take long-acting and meal-time insulin? Researchers will compare one dose of long-acting insulin per day to this plus three doses of short-acting insulin with each meal to see if blood sugars are controlled.\n\nParticipants will send their blood sugar logs to the study staff weekly, instead of to their OB\u002FGYN, for adjustments to their insulin dosing.",[26,64],"Gestational Diabetes",[66,67,68,69,70,71],"insulin glargine","insulin lispro","gestational diabetes","diabetes","pregnancy","noninferiority","2026-04-13",{"date":74,"type":39},"2026-04-16",{"date":76,"type":39},"2025-11-26",{"date":78,"type":21},"2027-05-15",{"name":80,"class":46},"Rutgers, The State University of New Jersey",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":59,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100543383","effects-of-moderate-carbohydrate-consumption-on-metabolic-and-obstetric-outcomes-in-pregnant-women-with-insulin-treated-diabetes--a-randomized-controlled-trial-100543383","NCT06355154","Effects of Moderate Carbohydrate Consumption on Metabolic and Obstetric Outcomes in Pregnant Women With Insulin-treated Diabetes- A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Pregnant women with singleton pregnancies.\n\n  * Over 18 years old.\n  * Diagnosis of GDM- 3-h 100-g OGTT according to the American College of Obstetricians and Gynecologists supported by the American Diabetes Association, Or Diagnosis of type 1 or 2 diabetes before pregnancy, Or Diagnosis of early GDM by either OGTT in the first trimester or elevated blood glucose measurements in the fasting (above 95mg\u002Fdl) or the postprandial (above 140 mg\u002Fdl) state.\n  * Are already on or intended to start intensive insulin treatment (at leased 2 injections of insulin per day) or wear an insulin pump.\n  * Are willing to wear a continuous glucose monitoring system.\n  * BMI of 18.5-42 kg\u002Fm2 at the time of diagnosis.\n\nExclusion Criteria:\n\n* Individual with risk factors for:\n\n  * Placental insufficiency.\n  * Hypertension.\n  * Renal disease.\n  * Thrombophilia\n  * Rheumatologic disease.\n  * A history of preeclampsia, or fetal growth restriction (IUGR).\n  * Individuals with a history of preterm labor, or concomitant therapy with β-blockers or glucocorticoids.\n  * Individuals who smoke and\u002For consume any amount of alcohol during pregnancy.","45 Years",{"count":90,"type":21},120,[61],"Diabetes during pregnancy increases maternal and fetal complications, necessitating optimal glycemic control. The standard care diet (SCD, ≥175g\u002Fday carbohydrate) lacks robust evidence, particularly for pregnancies requiring intensive insulin treatment (IIT). This RCT investigates whether a moderate carbohydrate diet (MCD, ≤120g\u002Fday) versus SCD improves glycemic control and alters metabolomic profiles in pregnant individuals on IIT.\n\nAims: To compare the efficacy and safety of a SCD versus MCD on glycemic control, metabolomic signatures, and pregnancy outcomes in pregnant individuals on IIT.",[26],[95,96,97,98,99],"Diabetes in pregnancy","Glycemic balance","Low Carbohydrates","Time in range","Ketosis","2025-09-29",{"date":102,"type":39},"2025-10-02",{"date":104,"type":39},"2024-05-28",{"date":106,"type":21},"2028-02-01",{"name":108,"class":46},"Hadassah Medical Organization",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":116,"targetDuration":4,"studyType":59,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":47},"100605654","injection-ports-vs-single-use-needles-for-insulin-in-pregnancy-effects-on-adherence-and-satisfaction-100605654","NCT07165327","Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction","Injection Ports Versus Single-Use Needles for Insulin Administration in Diabetic Pregnancies: Impact on Dose Adherence and Patient Satisfaction","Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus or gestational diabetes who require a multi-dose insulin regimen\n\nExclusion Criteria:\n\n* T1DM, primary language non-English or Spanish, use of an insulin pump",{"count":117,"type":21},44,[61],"This study wants to find out if using an injection port to give insulin during pregnancy helps people take their insulin more regularly and feel better about their care.\n\nWhen someone has diabetes during pregnancy, it's very important to keep their blood sugar levels in a healthy range. This usually means checking blood sugar often and giving insulin through shots. But giving many shots each day can be hard and uncomfortable.\n\nAn injection port is a small device placed on the skin that lets patients give insulin through the same spot without poking themselves each time. This may make taking insulin easier and less painful.\n\nFeeling comfortable with how insulin is given may help people stick to their treatment plan and have better health during pregnancy. Injection ports have already helped other patients, including pregnant people who needed other medications, but they haven't been studied for insulin use during pregnancy. This study will look at how pregnant patients with diabetes feel about using injection ports for insulin.",[121,25,26,122,123],"Gestatiaonl Diabetes Mellitus","Insulin Dependent Diabetes Mellitus","Insulin",[125,126,127,128,129,130,131,132,133],"Gestational diabetes","Type 2 diabetes in pregnancy","Insulin administration","Injection port","Single-use needles","Dose adherence","Patient satisfaction","Insulin delivery devices","Pregnancy diabetes management","NOT_YET_RECRUITING","2025-09-02",{"date":137,"type":39},"2025-09-10",{"date":139,"type":21},"2025-10",{"date":141,"type":21},"2026-10",{"name":143,"class":46},"University of Texas at Austin",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":88,"enrollmentInfo":152,"targetDuration":4,"studyType":59,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":47},"100540647","hydroxychloroquine-in-type-2-diabetes-during-pregnancy-100540647","NCT06319560","Hydroxychloroquine in Type 2 Diabetes During Pregnancy","Hydroxychloroquine as an Adjunct Therapy in the Management of Type 2 Diabetes in Pregnancy: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Singleton\n* Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus\n\nExclusion Criteria:\n\n* autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease\n* chronic kidney disease\n* fetal anomaly\n* women on steroid therapy\n* diabetic retinopathy\n* known thalassaemia or thalassaemia carrier","20 Years",{"count":153,"type":21},56,[61],"The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy?\n* Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment",[26,157],"Type 2 Diabetes",[69,70,159],"hydroxychloroquine","2025-06-09",{"date":162,"type":39},"2025-06-12",{"date":164,"type":39},"2024-03-24",{"date":166,"type":21},"2027-01-01",{"name":168,"class":46},"National University of Malaysia"]